Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment.

doi:10.1016/j.rec.2019.09.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment.

Revista espanola de cardiologia (English ed.) - 1 Mar 2020

Ravassa Susana, González Arantxa, Bayés-Genís Antoni, Lupón Josep, Díez Javier

Abstract excerpt

Myocardial interstitial fibrosis is a constant pathological finding in structural heart diseases of various etiologies that evolve with heart failure. Although fibrosis facilitates heart failure progression, until now no therapeutic strategy has been developed that ensures its reversal. A possible explanation for this may lie in the vision of myocardial interstitial fibrosis as a homogeneous lesion instead of a...

Topics

Biomarkers
Collagen Type I
Disease Progression
Fibrosis
Heart Failure
Humans
Hypertension
Myocardium
Phenotype
Precision Medicine
Proof of Concept Study

Source

Open in PubMed

Identifiers

PMID: 31759935
DOI: 10.1016/j.rec.2019.09.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics